Lindis biotech presents encouraging data from bladder cancer trial
Data revealed that 100% of patients achieved a complete remission with no recurrence
Read More
Tag: lindis
- Survodutide trial data show targeted visceral and liver fat reductions
- Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
- European approval enables measles protection with CSL’s immunoglobulin Privigen
- JJP Biologics reports positive interim phase 1b data for nebaprubart
- Immunotherapy boost can spare more bladder cancer patients major surgery
